The European Commission granted Marketing Authorisation for VUEWAY® (gadopiclenol ) for its use in pediatric patients under 2 years Bracco Imaging S.p.A., a global leader in diagnostic imaging, announces announces that on January 23, 2026, the European Commission (EC) granted the Marketing Authorisation for gadopiclenol in the European Union (EU) for pediatric patients below 2 years of age. 

The Sound of Innovation in Crete A new chapter of innovation unfolded on October 9, 2025, in Heraklion, Crete, during the Annual Meeting of the European Society of Medical Imaging Informatics (EuSoMII). In this context, the third edition of the EuSoMII/Bracco AI Contest took place—a unique, hands-on challenge designed to engage new generations of professionals in applying AI to real-world diagnostic problems.

The European Commission granted Marketing Authorisation for gadopiclenol for its use in pediatric patients under 2 years Bracco Imaging S.p.A., a global leader in diagnostic imaging, announces announces that on January 23, 2026, the European Commission (EC) granted the Marketing Authorisation for gadopiclenol in the European Union (EU) for pediatric patients below 2 years of age. 

Bracco and EuSoMII together at ECR – Hands on Challenge on Agentic AI Join us for an immersive, 2-hour hands-on challenge that brings the cutting edge of Agentic AI directly to the ECR floor. In this exclusive competition, 21 teams (2-3 participants each) will harness the power of mAIstro, a novel framework for orchestrating AI agents, to tackle complex workflows in brain tumor analysis.

Bracco Announces EU Launch of AiMIFY and Expands AI Portfolio At the 2026 European Congress of Radiology (ECR), Bracco Imaging S.p.A. today announced two major milestones in its AI & Digital Health strategy: the commercial launch in the European Union of AiMIFY® and a new strategic partnership with Avicenna.AI.

Bracco Invests in GMP Manufacturing Facility for Cell Therapy Product Facility upgrades support clinical-grade manufacturing of Bracco’s microbubble-based cell selection and activation technology. GMP readiness expected mid-2027.

Bracco Receives Health Canada Approval for gadopiclenol injection, Advancing Lower-Dose MRI Contrast Imaging

Bracco Receives Health Canada Approval for VUEWAY® injection (gadopiclenol), Advancing Lower-Dose MRI Contrast Imaging

BubbleGen™ Early Access Program Developed by Bracco, BubbleGen™ microbubbles build on more than two decades of use in diagnostic imaging and offer a bead-free alternative to traditional magnetic approaches.

Energy management